Advanced search×

Clinical Therapeutics

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Gale, Ingenta, Rcgp, and Sciencedirect from 1995

  1. Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors

    Clinical Therapeutics 37(9):1975 (2015) PMID 26164785 PMCID PMC4568126

    Purpose Glaucoma medications can improve clinical outcomes when patients adhere to their medication regimen. Providers often ask patients with glaucoma to self-report their adherence, but the accuracy of self-reporting has received little scientific attention. The purpose of ...
  2. Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis

    Clinical Therapeutics 37(9):2028 (2015) PMID 26210073

    Purpose The use of intravenous golimumab (GLM-IV), in combination with methotrexate, was approved by the US Food and Drug Administration in July 2013 for the treatment of moderate to severe, active rheumatoid arthritis (RA). GLM-IV is available in 50-mg vials, and the prescri...
  3. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition

    Clinical Therapeutics 37(9):2059 (2015) PMID 26256429

    Purpose Levomilnacipran, a selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor, is approved for the treatment of major depressive disorder (MDD) in adults. The objectives of this investigation were to characterize the pharmacokinetic (PK) parameters of levom...
  4. Cost–benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis

    Clinical Therapeutics 37(9):2019 (2015) PMID 26188835

    Purpose Posaconazole is effective for the prophylaxis of invasive fungal infections (IFIs) in patients with acute myeloid leukemia or myelodysplastic syndrome during remission induction chemotherapy. However, a cost–benefit analysis of posaconazole versus fluconazole or itrac...
  5. Medication Extraction from Electronic Clinical Notes in an Integrated Health System: A Study on Aspirin Use in Patients with Nonvalvular Atrial Fibrillation

    Clinical Therapeutics 37(9):2048 (2015) PMID 26233471

    Purpose The purpose of this study was to investigate whether aspirin use can be captured from the clinical notes in a nonvalvular atrial fibrillation population.
  6. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection

    Clinical Therapeutics 37(9):1876 (2015) PMID 26319088

    Purpose This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug interactions, and dosing and administration of cobicistat.
  7. Editorial Board
    Author(s) unavailable

    Clinical Therapeutics 37(9):A2 (2015)

  8. Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator–activated Receptor-γ Agonist, in Healthy Subjects

    Clinical Therapeutics 37(9):1999 (2015) PMID 26163202

    Purpose Lobeglitazone, a peroxisome proliferator–activated receptor-γ agonist, was developed for the treatment of diabetes mellitus. Because the prevalence of hypertension is high among patients with diabetes mellitus, lobeglitazone is likely to be used with the antihypertens...
  9. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis

    Clinical Therapeutics 37(9):2086 (2015) PMID 26254276

    Purpose The aim of this meta-analysis was to evaluate the benefits and potential adverse effects of adding spironolactone to standard antidiabetic/renoprotective/antihypertensive (AD/RP/AHT) treatment in patients with diabetic nephropathy (DN).
  10. Cost of Bleeding in Trauma and Complex Cardiac Surgery

    Clinical Therapeutics 37(9):1966 (2015) PMID 26210074

    Purpose Trauma and complex cardiac surgery are associated with a high risk of bleeding complications. The difference in costs between patients who require bleeding control measures and those who do not is poorly understood. Our goal was to assess the cost of care and outcomes...